Dentists in Ellettsville, IN Accepting Medicare
5 Dentists found. Showing 1 - 5
 David C. Walden, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 319 W Temperance St, Ellettsville, IN 47429 Phone: 812-876-4624 Fax: 812-876-8319 |
David C Compton, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 5915 West Highway 46, Ellettsville, IN 47429 Phone: 812-876-7330 Fax: 812-876-7325 |
Dr. Stephen Andrew Trager, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 5915 West State Road 46, Ellettsville, IN 47429 Phone: 812-876-7330 Fax: 812-876-7325 |
Ronald E. Deckard, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 7850 N Rodeo Dr, Ellettsville, IN 47429 Phone: 812-876-7026 |
Dr. Steven William Bollinger, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 5915 W. Highway 46, Ellettsville, IN 47429 Phone: 812-876-7330 Fax: 812-876-7325 |
News Archive
Men with short telomeres may have a greater risk for heart disease
Men with short telomeres - repetitive strips of DNA that cap the ends of chromosomes - may have a higher risk of developing coronary heart disease than those with long telomeres, according to an Article in this week's issue of The Lancet.
African-American couples with HIV can benefit from health promotion interventions
Interventions to promote healthy behaviors, including eating more fruits and vegetables, increasing physical activity, and participating in cancer screenings, as well as prevention of HIV/sexually transmitted diseases, appear beneficial for African-American couples who are at high risk for chronic diseases, especially if one of the individuals is living with HIV.
New project to develop blood tests for heart disease and stroke
The landmark Framingham Heart Study (FHS) is launching a major initiative to discover risk factors and markers that could lead to new blood tests to identify individuals at high risk of heart disease and stroke.
FDA grants "Fast Track" designation for Genta's advanced gastric cancer drug tesetaxel
Genta Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's request for "Fast Track" designation of tesetaxel for treatment of patients with advanced gastric cancer. Tesetaxel - a late Phase 2 oncology product - is the leading oral taxane currently in clinical development.
› Verified 3 days ago
Dentists
Counselors
Clinical Social Workers
Occupational Therapists